Literature DB >> 25240614

The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.

Quaovi Sodji1, Vishal Patil1, Surendra Jain2, James R Kornacki3, Milan Mrksich3, Babu L Tekwani4, Adegboyega K Oyelere5.   

Abstract

Histone deacetylase inhibitors (HDACi) pleiotropy is largely due to their nonselective inhibition of various cellular HDAC isoforms. Connecting inhibition of a specific isoform to biological responses and/or phenotypes is essential toward deconvoluting HDACi pleiotropy. The contribution of classes I and II HDACs to the antileishmanial activity of HDACi was investigated using the amastigote and promastigote forms of Leishmania donovani. We observed that the antileishmanial activities of HDACi are largely due to the inhibition of HDAC6-like activity. This observation could facilitate the development of HDACi as antileishmanial agents.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3-Hydroxypyridin-2-thione; Histone deacetylase inhibitors; Leishmania donovani; Trichostatin A; Tubastatin A

Mesh:

Substances:

Year:  2014        PMID: 25240614      PMCID: PMC4225773          DOI: 10.1016/j.bmcl.2014.08.060

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  30 in total

1.  A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors.

Authors:  William Guerrant; Sandra C Mwakwari; Po C Chen; Shabana I Khan; Babu L Tekwani; Adegboyega K Oyelere
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

2.  Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.

Authors:  Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

3.  The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.

Authors:  N K Verma; C S Dey
Journal:  Diabetologia       Date:  2006-05-03       Impact factor: 10.122

4.  A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue.

Authors:  J Mikus; D Steverding
Journal:  Parasitol Int       Date:  2000-01       Impact factor: 2.230

5.  Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation.

Authors:  Shannon E Mullican; Christine A Gaddis; Theresa Alenghat; Meera G Nair; Paul R Giacomin; Logan J Everett; Dan Feng; David J Steger; Jonathan Schug; David Artis; Mitchell A Lazar
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

6.  Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase.

Authors:  S J Darkin-Rattray; A M Gurnett; R W Myers; P M Dulski; T M Crumley; J J Allocco; C Cannova; P T Meinke; S L Colletti; M A Bednarek; S B Singh; M A Goetz; A W Dombrowski; J D Polishook; D M Schmatz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  Proof of interaction between Leishmania SIR2RP1 deacetylase and chaperone HSP83.

Authors:  Monte-Alegre Adriano; Baptiste Vergnes; Joel Poncet; Françoise Mathieu-Daude; Anabela Cordeiro da Silva; Ali Ouaissi; Denis Sereno
Journal:  Parasitol Res       Date:  2006-11-10       Impact factor: 2.289

Review 8.  Chemotherapy of leishmaniasis: past, present and future.

Authors:  Jyotsna Mishra; Anubha Saxena; Sarman Singh
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.

Authors:  Vishal Patil; William Guerrant; Po C Chen; Berkley Gryder; Derek B Benicewicz; Shabana I Khan; Babu L Tekwani; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2009-10-27       Impact factor: 3.641

10.  Inhibition of Plasmodium falciparum proliferation in vitro by double-stranded RNA directed against malaria histone deacetylase.

Authors:  N Sriwilaijaroen; S Boonma; P Attasart; J Pothikasikorn; S Panyim; W Noonpakdee
Journal:  Biochem Biophys Res Commun       Date:  2009-01-31       Impact factor: 3.575

View more
  2 in total

Review 1.  Histone deacetylases as targets for antitrypanosomal drugs.

Authors:  Aline A Zuma; Wanderley de Souza
Journal:  Future Sci OA       Date:  2018-07-27

2.  Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress.

Authors:  Rubens Lima do Monte Neto; Paulo Otávio Lourenço Moreira; Alessandra Mara de Sousa; Miguel Antonio do Nascimento Garcia; Suellen Rodrigues Maran; Nilmar Silvio Moretti
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-03-23       Impact factor: 2.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.